Metagenomi director granted 21,000 stock options

Metagenomi Therapeutics director Eric Bjerkholt received a grant of stock options covering 21,000 shares of common stock.

Rhea-AI Filing Summary

Metagenomi Therapeutics director Eric Bjerkholt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and give the right to buy 21,000 shares once vested.

The options vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date. Following this grant, his reported holdings of this option award total 21,000 derivative securities.

Insider Trade Summary

Grant/Award: 21,000 shares

Grant/Award 1 txn

Insider BJERKHOLT ERIC

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	21,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Key Figures

Option grant size: 21,000 shares Exercise price: $1.23 per share Underlying shares: 21,000 shares +2 more

5 metrics

Option grant size 21,000 shares Stock Option (Right to Buy) granted to director

Exercise price $1.23 per share Conversion or exercise price of stock option

Underlying shares 21,000 shares Common Stock underlying the option grant

Post-grant option holdings 21,000 options Total derivative securities following transaction

Option expiration June 8, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), exercise price, Grant, award, or other acquisition, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.2300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of stockholders financial

"the date of the Company's 2027 annual meeting of stockholders"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable upon the earlier of"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Metagenomi Therapeutics (MGX) report for Eric Bjerkholt?

Metagenomi Therapeutics reported a stock option grant to director Eric Bjerkholt. He received options covering 21,000 shares of common stock at an exercise price of $1.23 per share, increasing his derivative-based exposure to the company’s stock.

How many Metagenomi Therapeutics (MGX) shares are covered by the new stock options?

The new option grant covers 21,000 shares of Metagenomi common stock. These options give the director the right to purchase up to 21,000 shares upon vesting and exercise, aligning part of his compensation with future share performance.

What is the exercise price of Eric Bjerkholt’s Metagenomi (MGX) stock options?

The stock options have an exercise price of $1.23 per share. This means he can buy Metagenomi common shares at $1.23 once the options vest and are exercised, regardless of the market price at that time.

When do Eric Bjerkholt’s Metagenomi (MGX) stock options vest?

The options vest on the earlier of two dates. They become exercisable on the one-year anniversary of the grant date or on the date of Metagenomi’s 2027 annual meeting of stockholders, assuming his continued service through that vesting date.

Is Eric Bjerkholt’s Metagenomi (MGX) option grant an open-market purchase or compensation award?

The transaction is a compensation-related stock option award, not an open-market purchase. It is reported with code “A” as a grant or award acquisition and carries an exercise price of $1.23 per share for 21,000 underlying shares.

How many Metagenomi (MGX) stock options does Eric Bjerkholt hold after this grant?

After this grant, his reported holdings for this option award total 21,000 derivative securities. These options each relate to one share of common stock and are held directly, subject to the vesting terms described in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 01:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O METAGENOMI THERAPEUTICS, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.23	06/09/2026		A		21,000		(1)	06/08/2036	Common Stock	21,000	$0	21,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

	/s/ Matthew L. Wein, attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)